

# SAFETY DATA SHEET

according to the Globally Harmonized System



## Moxifloxacin Liquid Formulation

Version  
3.0

Revision Date:  
17.06.2025

SDS Number:  
1732584-00016

Date of last issue: 14.04.2025  
Date of first issue: 05.06.2017

---

### 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Moxifloxacin Liquid Formulation

#### Manufacturer or supplier's details

Company : MSD

Address : Briahnager - Off Pune Nagar Road  
Wagholi - Pune - India 412 207

Telephone : +1-908-740-4000

Emergency telephone number : +1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

#### Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

---

### 2. HAZARDS IDENTIFICATION

#### Manufacture, Storage and Import of Hazardous Chemicals Rules 1989

##### Classification

Not classified as hazardous according to criteria laid down in Part I of Schedule-1.

##### GHS Classification

Not a hazardous substance or mixture.

##### GHS label elements

No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required.

##### Other hazards which do not result in classification

None known.

---

### 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

#### Components

Chemical name	CAS-No.	Concentration (%) w/w)
Moxifloxacin HCL	186826-86-8	>= 0.1 - < 1

---

### 4. FIRST AID MEASURES

# SAFETY DATA SHEET

according to the Globally Harmonized System



## Moxifloxacin Liquid Formulation

Version 3.0      Revision Date: 17.06.2025      SDS Number: 1732584-00016      Date of last issue: 14.04.2025  
Date of first issue: 05.06.2017

---

General advice	: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	: If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	: In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	: Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.
If swallowed	: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	: None known.
Protection of first-aiders	: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	: Treat symptomatically and supportively.

---

## 5. FIREFIGHTING MEASURES

Suitable extinguishing media	: Water spray Alcohol-resistant foam Carbon dioxide (CO <sub>2</sub> ) Dry chemical
Unsuitable extinguishing media	: None known.
Specific hazards during fire-fighting	: Exposure to combustion products may be a hazard to health.
Hazardous combustion products	: No hazardous combustion products are known
Specific extinguishing methods	: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for firefighters	: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

## 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protection : Use personal protective equipment.

# SAFETY DATA SHEET

according to the Globally Harmonized System



## Moxifloxacin Liquid Formulation

Version  
3.0

Revision Date:  
17.06.2025

SDS Number:  
1732584-00016

Date of last issue: 14.04.2025  
Date of first issue: 05.06.2017

tive equipment and emergency procedures

Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions

- : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Prevent spreading over a wide area (e.g. by containment or oil barriers).  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up

- : Soak up with inert absorbent material.  
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.  
Clean up remaining materials from spill with suitable absorbent.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

---

## 7. HANDLING AND STORAGE

Technical measures

- : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation

- : Use only with adequate ventilation.

Advice on safe handling

- : Avoid inhalation of vapour or mist.

Do not swallow.

Avoid contact with eyes.

Avoid prolonged or repeated contact with skin.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment

Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage

- : Keep in properly labelled containers.

Store in accordance with the particular national regulations.

Materials to avoid

- : Do not store with the following product types:

Strong oxidizing agents

---

## 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

### Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis
Moxifloxacin HCL	186826-86-8	TWA	1000 µg/m <sup>3</sup> (OEB 1)	Internal

# SAFETY DATA SHEET

according to the Globally Harmonized System



## Moxifloxacin Liquid Formulation

Version  
3.0

Revision Date:  
17.06.2025

SDS Number:  
1732584-00016

Date of last issue: 14.04.2025  
Date of first issue: 05.06.2017

---

### Engineering measures

- : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections). All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Laboratory operations do not require special containment.

### Personal protective equipment

Respiratory protection	: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type	: Particulates type
Hand protection	: Chemical-resistant gloves
Material	
Eye protection	: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Skin and body protection	: Work uniform or laboratory coat.
Hygiene measures	: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

---

## 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	: liquid
Colour	: yellow
Odour	: odourless
Odour Threshold	: No data available
pH	: 4.1 - 4.6
Melting point/freezing point	: No data available
Initial boiling point and boiling range	: No data available
Flash point	: No data available

# SAFETY DATA SHEET

according to the Globally Harmonized System



## Moxifloxacin Liquid Formulation

Version 3.0      Revision Date: 17.06.2025      SDS Number: 1732584-00016      Date of last issue: 14.04.2025  
Date of first issue: 05.06.2017

---

Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available
Relative density	:	No data available
Density	:	1.0044 g/cm <sup>3</sup> (20 °C)
Solubility(ies)		
Water solubility	:	slightly soluble
Partition coefficient: n-octanol/water	:	No data available
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle characteristics		
Particle size	:	No data available

---

## 10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	Can react with strong oxidizing agents.
Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

# SAFETY DATA SHEET

according to the Globally Harmonized System



## Moxifloxacin Liquid Formulation

Version  
3.0

Revision Date:  
17.06.2025

SDS Number:  
1732584-00016

Date of last issue: 14.04.2025  
Date of first issue: 05.06.2017

### 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure : Inhalation  
Skin contact  
Ingestion  
Eye contact

#### Acute toxicity

Not classified based on available information.

#### Components:

##### Moxifloxacin HCL:

Acute oral toxicity	: LD50 (Rat): 1,320 mg/kg
	LD50 (Mouse): > 435 mg/kg
	LD50 (Monkey): 1,500 mg/kg

#### Skin corrosion/irritation

Not classified based on available information.

#### Components:

##### Moxifloxacin HCL:

Species	: Rabbit
Result	: No skin irritation

#### Serious eye damage/eye irritation

Not classified based on available information.

#### Components:

##### Moxifloxacin HCL:

Species	: Rabbit
Result	: Moderate eye irritation

#### Respiratory or skin sensitisation

##### Skin sensitisation

Not classified based on available information.

##### Respiratory sensitisation

Not classified based on available information.

##### Germ cell mutagenicity

Not classified based on available information.

#### Components:

##### Moxifloxacin HCL:

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES)
	Result: positive

# SAFETY DATA SHEET

according to the Globally Harmonized System



## Moxifloxacin Liquid Formulation

Version  
3.0

Revision Date:  
17.06.2025

SDS Number:  
1732584-00016

Date of last issue: 14.04.2025  
Date of first issue: 05.06.2017

		Test Type: Chromosome aberration test in vitro Result: negative
		Test Type: In vitro mammalian cell gene mutation test Result: negative
		Test Type: in vitro micronucleus test Result: negative
Genotoxicity in vivo	:	Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Application Route: Oral Result: negative

### Carcinogenicity

Not classified based on available information.

### Reproductive toxicity

Not classified based on available information.

### Components:

#### **Moxifloxacin HCL:**

Effects on fertility	:	Test Type: Fertility/early embryonic development Species: Rat Application Route: Oral Fertility: LOAEL: 500 mg/kg body weight Result: Effects on fertility
Effects on foetal development	:	Test Type: Embryo-foetal development Species: Monkey Application Route: Oral Developmental Toxicity: NOAEL: 10 mg/kg body weight Result: negative
		Test Type: Embryo-foetal development Species: Rabbit Application Route: Intravenous injection Developmental Toxicity: LOAEL: 20 mg/kg body weight Symptoms: Skeletal malformations
Reproductive toxicity - Assessment	:	Some evidence of adverse effects on development, based on animal experiments.

### **STOT - single exposure**

Not classified based on available information.

### **STOT - repeated exposure**

Not classified based on available information.

### Components:

#### **Moxifloxacin HCL:**

Target Organs	:	Liver
---------------	---	-------

# SAFETY DATA SHEET

according to the Globally Harmonized System



## Moxifloxacin Liquid Formulation

Version 3.0      Revision Date: 17.06.2025      SDS Number: 1732584-00016      Date of last issue: 14.04.2025  
Date of first issue: 05.06.2017

---

|| Assessment : May cause damage to organs through prolonged or repeated exposure.

### Repeated dose toxicity

#### Components:

##### **Moxifloxacin HCL:**

Species	:	Rat
LOAEL	:	100 mg/kg
Application Route	:	Oral
Exposure time	:	4 Weeks
Species	:	Rat
NOAEL	:	100 mg/kg
Application Route	:	Oral
Exposure time	:	13 Weeks
Target Organs	:	Liver
Symptoms	:	Liver disorders
Species	:	Rat
NOAEL	:	20 mg/kg
Application Route	:	Oral
Exposure time	:	6 Months
Target Organs	:	Liver
Symptoms	:	Liver disorders
Species	:	Monkey
NOAEL	:	50 mg/kg
Application Route	:	Oral
Exposure time	:	4 Weeks
Symptoms	:	No adverse effects
Species	:	Monkey
NOAEL	:	15 mg/kg
Application Route	:	Oral
Exposure time	:	13 Weeks
Target Organs	:	Gastrointestinal tract
Symptoms	:	Vomiting
Species	:	Monkey
Application Route	:	Oral
Exposure time	:	26 Weeks
Target Organs	:	Liver
Symptoms	:	Liver disorders

### Aspiration toxicity

Not classified based on available information.

### Experience with human exposure

#### Components:

##### **Moxifloxacin HCL:**

# SAFETY DATA SHEET

according to the Globally Harmonized System



## Moxifloxacin Liquid Formulation

Version  
3.0

Revision Date:  
17.06.2025

SDS Number:  
1732584-00016

Date of last issue: 14.04.2025  
Date of first issue: 05.06.2017



: Symptoms: Nausea, Abdominal pain, Headache, Dizziness, central nervous system effects, joint pain

## 12. ECOLOGICAL INFORMATION

### Ecotoxicity

No data available

### Persistence and degradability

No data available

### Bioaccumulative potential

No data available

### Mobility in soil

No data available

### Other adverse effects

No data available

## 13. DISPOSAL CONSIDERATIONS

### Disposal methods

Waste from residues : Do not dispose of waste into sewer.  
Dispose of in accordance with local regulations.  
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

## 14. TRANSPORT INFORMATION

### International Regulations

#### UNRTDG

Not regulated as a dangerous good

#### IATA-DGR

Not regulated as a dangerous good

#### IMDG-Code

Not regulated as a dangerous good

### Transport in bulk according to IMO instruments

Not applicable for product as supplied.

### Special precautions for user

Not applicable

## 15. REGULATORY INFORMATION

**Safety, health and environmental regulations/legislation specific for the substance or mixture**

**The components of this product are reported in the following inventories:**

AICS : not determined

# SAFETY DATA SHEET

according to the Globally Harmonized System



## Moxifloxacin Liquid Formulation

Version 3.0	Revision Date: 17.06.2025	SDS Number: 1732584-00016	Date of last issue: 14.04.2025 Date of first issue: 05.06.2017
----------------	------------------------------	------------------------------	---

---

DSL : not determined

IECSC : not determined

## 16. OTHER INFORMATION

Revision Date : 17.06.2025

### Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : dd.mm.yyyy

### Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECL - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

# SAFETY DATA SHEET

according to the Globally Harmonized System



## Moxifloxacin Liquid Formulation

Version  
3.0

Revision Date:  
17.06.2025

SDS Number:  
1732584-00016

Date of last issue: 14.04.2025  
Date of first issue: 05.06.2017

---

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IN / EN